Abbvie Inc (ABBV) Company Profile & Statistics

Abbvie Inc
ABBV
(NYSE)
Closed
176.95
+5.22 (+3.04%)
in:usd•As of: Nov 22, 2024 15:59 UTC -5
After Market:177.01+0.06 (+0.03%)
Open
174.58
High
178.86
Low
173.52

About Abbvie Inc

CEO

RichardA. Gonzalez

Headquarters

1 north waukegan road

north chicago, il 60064, united states

Auditor

Ernst & Young LLP

Employees

50,000

Share Holders

42,369

Website

www.abbvie.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq.

Abbvie Inc Statistics

Valuation Measures

Market Capitalization ²	312.70B
Enterprise Value	376.52B
Enterprise Value/EBITDA (ttm)	16.97
Price to Earnings Ratio (ttm)	15.49
Price to Book (mrq)	48.49
Price to Sales (ttm)	5.30
Price to Cash (ytd)	10.53

Profitability

Gross Margin (ttm)	67.17%
Operating Margin (ttm)	34.42%
Profit Margin (ttm)	9.28%
Return on Equity (ttm)	244.01%
Return on Invested Capital (ttm)	7.76%
Return on Assets (ttm)	13.44%

Income Statement

Revenue (ttm)	55.53B
Revenue Per Share (ttm)	31.43
Gross Profit (ttm)	37.32B
EBITDA (ttm)³	22.18B
Net Income Avi to Common (ttm)	5.12B
Diluted EPS (ttm)	2.88

Share Statistics

Beta (5Y Monthly)	0.63
52-Week Change	32.61%
S&P500 52-Week Change	30.93%
S&P500 Member	Yes
Stock Optionable	Yes
Total Shares Outstanding ¹	1.77B
Dividend Yield	3.72%
Float ⁴	1.76B
% Held by Insiders	0.25%
% Held by Institutions	70.23%

Balance Sheet

Total Cash (mrq)	7.29B
Total Cash Per Share (mrq)	4.12
Total Debt (mrq)	71.08B
Total Debt/Equity (mrq)	1170.80%
Current Ratio (mrq)	0.65%
Quick Ratio (mrq)	0.54%
Book Value Per Share (mrq)	3.44

Cash Flow

Operating Cash Flow Per Share (ytd)	6.64
Free Cash Flow (ytd)	11.07B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Abbvie Inc

Trade With A Regulated Broker